Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Avigan

Showing results (31-40 of 114) with videos related to

Pageof 12
Sort By:
European Journal of Immunology|July 28, 2009
Allogeneic induced human FOXP3(+)IFN-gamma(+) T cells exhibit selective suppressive capacityDina Stroopinsky, Irit Avivi, Jacob M Rowe, et al.
Bone Marrow Transplantation|May 26, 2018
Prevention and treatment of relapse after stem cell transplantation with immunotherapyNicola Gökbuget, Jonathan Canaani, Arnon Nagler, et al.
Blood|March 23, 2011
MUC1-C oncoprotein suppresses reactive oxygen species-induced terminal differentiation of acute myelogenous leukemia cellsLi Yin, Zekui Wu, David Avigan, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 9, 2005
Dendritic cells induce MUC1 expression and polarization on human T cells by an IL-7-dependent mechanismBaldev Vasir, David Avigan, Zekui Wu, et al.
Cancer Research|December 20, 2007
MUC1 oncoprotein regulates Bcr-Abl stability and pathogenesis in chronic myelogenous leukemia cellsTakeshi Kawano, Masaki Ito, Deepak Raina, et al.
Cancer Biology & Therapy|July 2, 2010
Terminal differentiation of chronic myelogenous leukemia cells is induced by targeting of the MUC1-C oncoproteinLi Yin, Rehan Ahmad, Michio Kosugi, et al.
Journal of Hematology|November 22, 2021
Progressive Multifocal Leukoencephalopathy After Chimeric Antigen Receptor T-Cell Therapy for Recurrent Non-Hodgkin LymphomaJared T Ahrendsen, Kartik Sehgal, Sasmit Sarangi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 21, 2008
Fusions of dendritic cells with breast carcinoma stimulate the expansion of regulatory T cells while concomitant exposure to IL-12, CpG oligodeoxynucleotides, and anti-CD3/CD28 promotes the expansion of activated tumor reactive cellsBaldev Vasir, Zekui Wu, Keith Crawford, et al.
Molecular Pharmacology|May 7, 2010
Survival of human multiple myeloma cells is dependent on MUC1 C-terminal transmembrane subunit oncoprotein functionLi Yin, Rehan Ahmad, Michio Kosugi, et al.
British Journal of Haematology|June 24, 2017
MUC1-C is a target in lenalidomide resistant multiple myelomaLi Yin, Ashujit Tagde, Reddy Gali, et al.
Pageof 12

Showing results (31-40 of 114) with videos related to

Sort By:
Pageof 12
European Journal of Immunology|July 28, 2009
Allogeneic induced human FOXP3(+)IFN-gamma(+) T cells exhibit selective suppressive capacityDina Stroopinsky, Irit Avivi, Jacob M Rowe, et al.
Bone Marrow Transplantation|May 26, 2018
Prevention and treatment of relapse after stem cell transplantation with immunotherapyNicola Gökbuget, Jonathan Canaani, Arnon Nagler, et al.
Blood|March 23, 2011
MUC1-C oncoprotein suppresses reactive oxygen species-induced terminal differentiation of acute myelogenous leukemia cellsLi Yin, Zekui Wu, David Avigan, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 9, 2005
Dendritic cells induce MUC1 expression and polarization on human T cells by an IL-7-dependent mechanismBaldev Vasir, David Avigan, Zekui Wu, et al.
Cancer Research|December 20, 2007
MUC1 oncoprotein regulates Bcr-Abl stability and pathogenesis in chronic myelogenous leukemia cellsTakeshi Kawano, Masaki Ito, Deepak Raina, et al.
Cancer Biology & Therapy|July 2, 2010
Terminal differentiation of chronic myelogenous leukemia cells is induced by targeting of the MUC1-C oncoproteinLi Yin, Rehan Ahmad, Michio Kosugi, et al.
Journal of Hematology|November 22, 2021
Progressive Multifocal Leukoencephalopathy After Chimeric Antigen Receptor T-Cell Therapy for Recurrent Non-Hodgkin LymphomaJared T Ahrendsen, Kartik Sehgal, Sasmit Sarangi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 21, 2008
Fusions of dendritic cells with breast carcinoma stimulate the expansion of regulatory T cells while concomitant exposure to IL-12, CpG oligodeoxynucleotides, and anti-CD3/CD28 promotes the expansion of activated tumor reactive cellsBaldev Vasir, Zekui Wu, Keith Crawford, et al.
Molecular Pharmacology|May 7, 2010
Survival of human multiple myeloma cells is dependent on MUC1 C-terminal transmembrane subunit oncoprotein functionLi Yin, Rehan Ahmad, Michio Kosugi, et al.
British Journal of Haematology|June 24, 2017
MUC1-C is a target in lenalidomide resistant multiple myelomaLi Yin, Ashujit Tagde, Reddy Gali, et al.
Pageof 12